Hepatitis B: Can It Be Cured or Only Managed?

The honest answer: chronic hepatitis B can be controlled — often very effectively — but it cannot yet be fully cured in most patients. Unlike hepatitis C, which is now curable in over 95% of patients with 8–12 weeks of oral medication, hepatitis B integrates its DNA into your liver cells — making complete elimination of the virus extraordinarily difficult with current technology. What treatment can achieve is functional cure in some patients and viral suppression in most — both of which dramatically reduce liver damage, cirrhosis progression, and liver cancer risk.

If you have chronic hepatitis B, understanding the difference between cure, functional cure, and viral suppression — and knowing which is achievable for you — is essential for managing expectations and making informed treatment decisions.

What makes hepatitis B different from hepatitis C

The fundamental difference is viral biology. Hepatitis C is an RNA virus that replicates in the cytoplasm of liver cells without integrating into your DNA. Kill the replicating virus → it's gone. Hepatitis B is a DNA virus that integrates a reservoir called cccDNA (covalently closed circular DNA) into the nucleus of your liver cells. This cccDNA is invisible to your immune system and resistant to current antiviral medications. Even when blood levels of the virus are undetectable and the liver is healthy, the cccDNA reservoir persists — capable of reactivating the virus if immunosuppression occurs or treatment is stopped.

This persistent reservoir is the reason chronic hepatitis B requires long-term management — and why "cure" is defined differently than for hepatitis C.

The three levels of hepatitis B control

Who needs treatment

Not everyone with chronic hepatitis B needs antiviral treatment immediately. The decision depends on your "phase" of infection — hepatitis B exists in several distinct phases based on the interaction between the virus and your immune system:

• Immune tolerant phase: High viral load but minimal liver inflammation (normal ALT). The immune system isn't actively fighting the virus. Treatment is generally not started — the goal is monitoring for transition to the immune active phase.

• Immune active phase (HBeAg-positive or negative): Elevated ALT, active viral replication, liver inflammation. This is when treatment is indicated — the immune system is attacking infected liver cells, causing damage that will lead to fibrosis if not suppressed.

• Inactive carrier state: Low or undetectable viral load, normal ALT, HBsAg-positive. The immune system has achieved partial control. Treatment may not be needed, but monitoring is essential — reactivation can occur.

• Any patient with cirrhosis: Treatment is indicated regardless of ALT or viral load — the liver can't afford additional insults.

• Any patient needing immunosuppression (chemotherapy, organ transplant, autoimmune disease treatment): Antiviral prophylaxis is essential to prevent reactivation.

The determination of which phase you're in requires serial blood tests (HBV DNA, HBeAg, ALT) over several months. Your hepatologist will monitor these trends — upload every lab report to LiverTracker so the trajectory is visible.

How treatment works

Nucleos(t)ide analogues (NAs): the backbone of HBV therapy

These oral medications block the viral enzyme (reverse transcriptase) that HBV uses to replicate. They don't eliminate the virus — they suppress it to undetectable or very low levels, stopping liver damage.

Treatment is typically lifelong — stopping NAs in most patients leads to viral rebound within weeks to months, and the rebound can cause severe hepatitis flares that damage the liver. Stopping therapy is only considered in carefully selected patients who have achieved HBeAg seroconversion (immune system actively controlling the virus) with sustained viral suppression for 12+ months — and even then, close monitoring is essential.

Pegylated interferon alfa (PEG-IFN)

A weekly injection that boosts your immune system's response to HBV. Treatment duration is finite (typically 48 weeks), and it has the highest rate of achieving functional cure (~10–15% HBsAg loss in selected patients). However, side effects are significant (fatigue, flu-like symptoms, depression, blood count suppression), and it's not suitable for patients with decompensated cirrhosis. PEG-IFN is used in selected patients — particularly younger patients with favorable predictors of response — not as universal first-line therapy.

The cure pipeline

Hepatitis B cure research is one of the most active fields in hepatology. Approaches in clinical trials include RNA interference (siRNA/antisense oligonucleotides) to silence cccDNA and reduce HBsAg, capsid assembly modulators (CAMs) that disrupt viral assembly, therapeutic vaccines to boost anti-HBV immune response, toll-like receptor agonists to stimulate innate immunity, gene editing (CRISPR-based approaches) to target cccDNA directly, and checkpoint inhibitors to reverse immune exhaustion. Several combination approaches are in Phase 2 and Phase 3 trials. A functional cure for a larger proportion of patients may become achievable within the next decade — but it's not available today.

HCC screening: the critical commitment

This is the section that can save your life. Hepatitis B increases liver cancer (HCC) risk even without cirrhosis — unlike most liver conditions where HCC risk requires cirrhosis to develop. HBV's DNA integration into liver cells can directly promote cancerous transformation independent of fibrosis stage.

Who needs HCC screening with HBV:

• All HBV patients with cirrhosis (any viral status)

• Asian males over 40 with chronic HBV

• Asian females over 50 with chronic HBV

• African/African American patients over 20 with chronic HBV

• Any patient with a family history of HCC

• Any patient with high HBV viral load or active hepatitis

Screening: AFP + abdominal ultrasound every 6 months. This is lifelong for all patients meeting the above criteria — even those on successful antiviral therapy with undetectable viral load. Treatment reduces but does not eliminate HCC risk.

Log every screening in the LiverTracker imaging tracker. Track your AFP trend on trend charts. Never miss a scheduled screening.

Living with chronic hepatitis B

• Take your antiviral medication consistently. Missing doses allows viral rebound. Set alarms. Use pill organizers. Treat it like brushing your teeth — non-negotiable, every single day.

• Zero alcohol. Alcohol + HBV accelerates liver damage synergistically. There is no safe amount.

• Get your household contacts and sexual partners vaccinated. Hepatitis B is preventable with vaccination. The HBV vaccine is >95% effective and provides lifelong protection. Everyone in your household, your sexual partners, and your close contacts should be vaccinated if they're not already immune.

• Inform your doctors before any immunosuppressive therapy. If you ever need chemotherapy, organ transplant medications, corticosteroids, or biologic drugs (for autoimmune conditions), your HBV status must be known — because immunosuppression can reactivate even "controlled" HBV, causing devastating hepatitis flares. Antiviral prophylaxis is started before immunosuppression and continued throughout.

• Monitor regularly. Labs (HBV DNA, ALT, liver panel) every 3–6 months on treatment. FibroScan periodically to assess fibrosis. HCC screening per the schedule above. Upload every lab report to LiverTracker.

• Pregnancy planning. If you're a woman with HBV planning pregnancy, discuss timing with your hepatologist. Tenofovir is safe during pregnancy and reduces mother-to-child transmission risk. All newborns of HBV-positive mothers should receive HBIG (hepatitis B immunoglobulin) + HBV vaccine within 12 hours of birth — this prevents perinatal infection in >95% of cases.

Frequently asked questions

Will hepatitis B ever be cured?

A true sterilizing cure (complete elimination of cccDNA) is not yet possible. But functional cure (HBsAg loss with immune control) is achievable in a small percentage of patients with current therapy, and combination approaches in clinical trials aim to expand this significantly. Most hepatologists are cautiously optimistic that functional cure for a larger proportion of patients will become available within the next 5–10 years. In the meantime, viral suppression with NAs is highly effective at preventing liver damage.

Can I stop taking antiviral medication?

In most cases, no — stopping leads to viral rebound and potential hepatitis flare within weeks to months. Carefully selected patients who have achieved HBeAg seroconversion with sustained viral suppression for 12+ months may attempt cessation under close monitoring — but even then, relapse occurs in 40–60% of patients. Never stop your antiviral without explicit hepatologist guidance and a monitoring plan.

Is hepatitis B contagious?

Yes — through blood and bodily fluids (sexual contact, sharing needles, mother-to-child during birth, blood exposure). It is NOT transmitted through casual contact, sharing food, coughing, sneezing, or breastfeeding. Vaccination of your household contacts and sexual partners is the most important prevention step.

Can I have hepatitis B and C at the same time?

Yes — co-infection occurs and requires careful management. Treating hepatitis C in a co-infected patient can sometimes reactivate hepatitis B (as the immune system shifts its response). If you have both, your hepatologist will coordinate treatment carefully — typically starting HBV antiviral prophylaxis before or during HCV treatment.

Does hepatitis B cause liver cancer even without cirrhosis?

Yes — this is unique to HBV among viral hepatitis infections. HBV DNA integrates into liver cell DNA and can promote carcinogenesis directly, independent of fibrosis. This is why HCC screening is recommended for specific HBV patient groups regardless of fibrosis stage — something that doesn't apply to most other liver conditions.

Hepatitis B isn't curable yet — but it's controllable. One pill a day suppresses the virus in over 90% of patients. The commitment is consistency: daily medication, regular monitoring, and lifelong HCC screening. Do those three things, and your liver has every chance of lasting as long as you do.

→ Check Your Liver Enzymes Free

→ Start Tracking Free

→ Log Your HCC Screenings

Medical Disclaimer: This article is for informational and educational purposes only. Hepatitis B management should be directed by a hepatologist. Never stop antiviral medication without medical guidance. Visit livertracker.com/medical-disclaimer.